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Edited by Felix WielandAbstract 25-Acetyl-petrosaspongiolide M (PMAc) (1), a mild
non-covalent PLA2 inhibitor, unexpectedly recovers, after incu-
bation with bvPLA2, the ability to covalently modify the enzyme
target. This study demonstrates the catalytic eﬀect of bvPLA2 in
converting 1 in its deacetylated congener petrosaspongiolide M
(PM) (2), a strong covalent PLA2 inhibitor whose molecular
mechanism of inhibition has already been clariﬁed. Moreover,
our ﬁndings outline the potential role of PMAc as anti-inﬂam-
matory pro-drug, by virtue of its ability of delivering the active
PM agent at the site of inﬂammation, functioning as a suicide
inhibitor.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Marine sesterterpenes containing a c-hydroxybutenolide
ring are well known to speciﬁcally inhibit PLA2 enzymes
[1–7]. Among them, petrosaspongiolides M-R, isolated in
1997 from the marine sponge Petrosaspongia nigra [8], have
recently become the subject of extensive investigation in
our laboratory, in the attempt to clarify their mechanism
of inhibition and their interaction at the atomic level with
bvPLA2. The ultimate goal of our study is a deep compre-
hension of the principles underlying the mode of action of
this family of anti-inﬂammatory natural agents [9,10]. In
fact, armed with such knowledge, we aim at a rational design
of simpliﬁed inhibitors of PLA2 as potential new leads for
the treatment of inﬂammation-related diseases [11–19]. In
this context, bvPLA2 represents a very useful model for such
studies, as the pharmacological characterization of PM and
its derivatives has shown an excellent correlation between
inhibitory proﬁles obtained on this model (group III) enzymeAbbreviations: PLA2, Phospholipase A2; bvPLA2, bee venom PLA2
(PDB code: 1POC); DOPG, dioleoylphosphatidylglycerol; SUVs,
small unilamellar vesicles; RP-HPLC, Reverse Phase-High Perfor-
mance Liquid Cromatography; ESI-MS, electrospray mass spectrom-
etry; TFA, triﬂuoroacetic acid; CD, circular dichroism
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doi:10.1016/j.febslet.2004.10.100with respect to (group IIa) human secretory counterpart
(hsPLA2) [8,20].
Petrosaspongiolide M (PM) (2), the most active among pet-
rosaspongiolides [8,20,21], is able to covalently and speciﬁcally
modify bvPLA2 by means of a Schiﬀ base formation between
its C-25 masked aldehyde moiety (a cyclic hemiacetal function)
and the amino group of the N-terminal Ile-1 residue of the en-
zyme [9]. 3D models of the complexes between bvPLA2 and
petrosaspongiolides M and R, respectively, were obtained by
means of molecular modeling studies, leading us to a better
understanding of the enzyme inactivation process at a molecu-
lar level. Our ﬁndings strongly suggest that the covalent inter-
action responsible for the enzymatic inhibition is mediated by
a non-covalent molecular recognition event [10].
In the attempt to shed more light on the importance of such
non-covalent interactions in the inactivation of bvPLA2 by pet-
rosaspongiolides, we performed a comparative study on the
bvPLA2 inhibition proﬁles of PM (2) and 25-acetyl-PM
(PMAc) (1), a semi-synthetic derivative of PM, whose reactive





















MW=460 Da2. Materials and methods
2.1. Materials
All employed solvents and reagents were HPLC grade and were pur-
chased from Baker and Fluka, respectively. bvPLA2, oleic acid and
DOPG were purchased from Sigma–Aldrich and the ADIFAB kit
was purchased from ICN Biomedicals.
2.2. Phospholipase A2 kinetic assay
The application of a ﬂuorescence displacement assay to PLA2 kinetics
has been described previously [22–25]. Our experimental procedure was
carried out using the ﬂuorescent probeADIFAB (ICNpharmaceuticals)
consisting in an acrylodan derivative of rat intestinal fatty acid binding
protein that exhibits a change in the ﬂuorescence (D Ratio 490/440 nm)ation of European Biochemical Societies.
270 M.C. Monti et al. / FEBS Letters 578 (2004) 269–274upon binding long-chain native fatty acids [23]. Measurements of the
490/440 intensity ratio (R values) were done on a Perkin Elmer LS55
Luminescence Spectrometer with excitation at 386 nm, excitation slit
at 4 nm and emission slit at 8 nm. Calibration of ﬂuorescence displace-
ment was performed using oleic acid as standard. All assays were carried
out at 37 C and each measurement was repeated three times and values
represented the means ± standard deviation (S.D.).
In order to obtain phospholipid substrate at a concentration of 60
lM in the form of SUVs, a stock solution of DOPG (10 mg/ml in
methanol) was diluted in the assay buﬀer (10 mM HEPES, 150 mM
NaCl, 5 mM KCl, 1 mM NaHPO4, 1 mM Glucose, 1 mM MgCl2
and 1 mM CaCl2 at pH 7.4) by rapid injection [24].
Aliquots of the assay buﬀer containing the substrate at various con-
centrations, from 0.02 to 1 lM, and 20 nM ADIFAB kit were placed in
the cuvette and the R value of the solution was registered for 1 min.
Then, bvPLA2 (ﬁnal concentration 1 nM) was added and the enzyme
activity was monitored for 3000 s with an integration time of 2.0 s.
2.3. Kinetic analysis of inhibition
Aliquots of bvPLA2 (500 fmol) were incubated with diﬀerent
amounts of PMAc (molar ratio bvPLA2:PMAc from 1:0.5 to 1:40)
for 10 min at 37 C. Then, the mixture was placed in the cuvette with
the assay buﬀer containing the substrate (ﬁnal concentration 1 lM)
and the ADIFAB kit (ﬁnal concentration 20 nM) and the enzyme
activity (ﬁnal concentration 1 nM) was monitored.
Enzyme rates in the presence of inhibitors were then compared with
those measured for enzyme only.
2.4. Circular dichroism spectroscopy
Circular dichroism measurements were performed using a Jasco J-
810 spectrometer equipped with a cell holder thermostatically con-
trolled by a circulating water bath. Measurements were recorded at
25 C, with an 8 s time constant and 5 nm/min and averaged for eight
acquisitions. The protein concentration was 15 lM and spectra were
collected with rectangular quartz cells of 1 cm path length in the
near-UV region (320–250 nm). Adduct formation between bvPLA2
and PMAc was analyzed in a 10 mM sodium borate buﬀer, at pH
7.5, incubating the protein with 5:1 molar excess of ligand for 10
min at 37 C. Spectra were recorded before and after the addition of
the ligand and routinely corrected for the background signal and for
dilution eﬀects. Cotton eﬀects are reported as molar ellipticity.
2.5. Acetylation of petrosaspongiolide M (2)
25-Acetyl-PM and 25-[D3]acetyl-PM were prepared by using the
procedure reported by Randazzo et al. [8] starting from PM and acetic
anhydride or D6-acetic anhydride, respectively.
2.6. bvPLA2-inhibitor adducts analysis
PMAc and 25-[D3]acetyl-petrosaspongiolide M (D3-PMAc) were
dissolved in isopropyl alcohol (1 mg/ml) and then, individually, added
to a 100 ll of a solution of bvPLA2 (15 lM in sodium borate 10 mM,
CaCl2 10 mM at pH = 7.5) for 10 min at 37 C with a 5:1 molar excess
of inhibitor, in the presence of 20:1 molar excess of oleic acid. The ﬁnal
concentration of isopropyl alcohol in the reaction mixture was always
kept lower than 4% v/v. It is noteworthy that in our hands the presence
of oleic acid was deemed crucial for the eﬃcacy of esterase enzyme
catalysis.
When a reduction step was required, the sample was diluted with an
equal volume of a solution of NaBH4 in NaOH (15 mM) for 2 h at 0
C (molar ratio NaBH4:bvPLA2 = 400:1) and the reaction was
quenched adding 5 ll of 6 M HCl.2525
AcOH
PLA2-catalyzed
 hydrolysis H2O 25
Scheme 1. The postulated mechanism for PMAc-bvPLA2 iThe mixture of unreacted and monomodiﬁed protein was ana-
lyzed by RP-HPLC on a Phenomenex C4 narrow-bore column by
means of a linear gradient from 25% to 95% aqueous acetonitrile
containing 0.05% TFA, over 45 min at 0.2 ml/min. The elution pro-
ﬁle was monitored at 220 and 280 nm. The fractions were collected
and analyzed by an electrospray ion source at 220 C at a ﬂow rate
of 5 ll/min on a Finnigan LCQ Deca ion trap mass spectrometer
(ThermoQuest, San Jose´, California). Data were analyzed using
the suite of programs Xcalibur (ThermoQuest, San Jose´, Califor-
nia), while the Magtran software (Zhang and Marshall Zscore
Algorithm) was used for data processing; all masses were reported
as average values.
PM-oxyme (3) was observed upon treatment of the bvPLA2-
PMAc mixture with NH2OH (with a molar excess of NH2OH:pro-
tein of 1000:1) for 2 h at 37 C and an LC-MS analysis was per-
formed for the isolation and MS characterization of the various
species. The mixture was analyzed by RP-HPLC on a Phenomenex
C18 narrow-bore column by means of a linear gradient from 25% to
55% in 20 min and then from 55% to 95% in 50 min at a ﬂow rate
of 0.2 ml/min eluting with aqueous acetonitrile containing 0.05%
TFA.
The covalent adducts between bvPLA2 and PMAc and D3-PMAc,
respectively, were puriﬁed by HPLC and subjected to disulﬁde bond
reduction by DTT (5 mM) for 2 h at 37 C under nitrogen atmo-
sphere. Free thiol groups were then blocked by treatment with iodo-
acetamide (50 mM) for 30 min at room temperature in the dark and
the reaction was quenched by HPLC injection. The alkylated species
were digested with endoproteinase Lys C in ammonium bicarbonate
(50 mM, pH 8) at 37 C for 4 h with a 1:50 (w/w) LysC/adduct ratio.
Proteolytic fragments were analyzed by LC-MS performed on a
Finnigan LCQ Deca ion trap mass spectrometer equipped with
P4000 Spectra System quaternary pumps. Chromatographic separa-
tion was carried out on a Phenomenex C18 column by means of a
linear gradient from 15% to 55% acetonitrile in 2% formic acid and
0.1% TFA. Mass spectra were acquired in an m/z interval of 600–
1800.3. Results and discussion
Initially, the investigation on the biological properties of
PMAc was undertaken to gain insight on the nature and rele-
vance of non-covalent interactions in the PLA2 inhibition by
PM. Indeed, PMAc, with both its reactive centers (C-24 and
C-25 hemicetal functionalities) blocked as acetates, seemed to
be a logical choice for highlighting the non-covalent forces
shaping the PM-PLA2 recognition process. With this back-
ground, a selective and quite eﬃcient hydrolytic cleavage of
the 25-acetate was rather unexpected, also in consideration
that, to our knowledge, there are no documented examples
of PLA2 activity as generic esterase (Scheme 1).
Our study took advantage of the combined results of three
diﬀerent spectroscopic techniques: (a) comparative analysis
of the enzyme kinetics of inhibition by means of a ﬂuorescence
displacement assay; (b) CD analysis to monitor protein tertiary
structure changes associated to the inhibition process; and (c)




∆M = + 442 Da ∆M = + 444 Da
25 25
nactivation along with the expected mass increments.
Fig. 1. bvPLA2 inactivation kinetics caused by 1 and 2. Activities were
determined using the ADIFAB ﬂuorescence displacement assay and
are shown as relative percentages to enzymatic activity measured in the
absence of any inhibitor (set to 100%). Data refer to means ± S.D.
(n = 3). See Sections 3.1 and 2 for further details.
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In the aim to monitor the inhibition of bvPLA2 activity by
petrosaspongiolides, it was ﬁrst necessary to investigate kinetic
properties of bvPLA2 in our experimental conditions.
Experiments were carried out using the ﬂuorescent probe
ADIFAB (see also Section 2) and anionic vesicles of DOPG
as a substrate due to their high aﬃnity to bvPLA2 through
an interfacial binding [25]. To set up the right conditions for
subsequent assays of inhibition, the increase of enzyme activity
in the presence of various concentrations of DOPG was mon-
itored (data not shown) to allow us to optimize the concentra-
tion of DOPG for the inhibition assay.
Experiments were carried out by incubating bvPLA2 with the
inhibitors for 10 min and then adding the mixture to the stock
assay buﬀer containing the substrate SUVs and the ﬂuorescent
probe ADIFAB. Enzyme rates in the presence and in the ab-
sence of the two inhibitors under investigation were then com-
pared. In these conditions, as shown in the plots of Fig. 1,
PMAc gives rise only to a moderate PLA2 inhibition (if com-
pared to PM), due to its yet incomplete hydrolysis to PM.
Nonetheless, it is noteworthy that even after such a short incu-
bation time, PMAc shows already an inhibitory activity of
50% at 0.25 lM (vs. a 90% inhibition by intact PM at the same
concentration). In other words, the inhibitory potency of
PMAc, being directly correlated to its ability to revert to PM
in physiological conditions, varies with the time going, a fea-
ture typically shown by pro-drug molecules. Our results indi-Fig. 2. CD curves of free bvPLA2 and inccate that PMAc produces a steadily increasing concentration
of PM, the real (covalent) PLA2 inhibitor. After 60 min, PMAc
approaches the same inhibition power of PM (see also Fig. 3).
3.2. Circular dichroism analysis
In a second experiment, the incubation solution mixture of
bvPLA2 with PMAc (37 C, pH = 7, 10 min) was employed
for CD measurements [26,27]. The contribution of aromatic
side chains to the near-UV CD spectra of proteins is widely
recognized and utilized as a sensitive probe of protein confor-
mation and ligand binding [28–33]. We then used the near-UV
CD spectra of bvPLA2 for monitoring the changes in the ter-
tiary structure occurring to the enzyme upon binding of the
inhibitor. In the region between 250 and 320 nm, the CD signal
arises from the aromatic side chains, namely, two Trp, eight
Tyr and ﬁve Phe residues of bvPLA2. The changes observed
in such region of the CD curves relative to the free enzyme
and the incubation mixture with 1 (Fig. 2), respectively, clearly
indicated that a perturbation of the environment of the
aromatic side chains of bvPLA2 enzyme is induced by the
inhibitor.
3.3. Characterization of bvPLA2-PMAc covalent adduct
In the attempt to ascertain whether such tertiary structure
perturbation could be addressed to purely non-covalent inter-
actions between bvPLA2 and PMAc or, on the contrary, to a
chemical modiﬁcation of the enzyme, the incubation mixture
recovered after the CD measurement was submitted to over-
night dialysis against 10 mM sodium borate at pH 7.5 and then
analyzed again by CD and LC-MS. Unexpectedly, the CD re-
sponse resulted in a curve superimposable to the one detected
before dialysis. Moreover, the LC-MS analysis of the mixture
led to the recovery of the free enzyme along with a large
amount of a modiﬁed enzymatic species, featuring a MW in-
crease of 442 Da. Moreover, this species resulted unstable
upon acidiﬁcation (pH = 3) of the medium, disappearing from
the TIC trace of the LC-MS run, in agreement with the pres-
ence of a Schiﬀ base functionality reverting back to its car-
bonyl and amine components in acidic media.
A full characterization of the chemical behavior of PMAc
towards PLA2 was achieved by performing a HPLC-MS anal-
ysis of aliquots, collected at diﬀerent times, of the bvPLA2-
PMAc incubation mixture. The results provided evidence of
a time-dependent formation of the covalently modiﬁed
bvPLA2 species (Fig. 3). A parallel experiment was performed
in which the incubation mixture was treated with NaBH4ubation mixture of bvPLA2 with 1.
Fig. 4. LC-MS trace of the bvPLA2-PMAc incubation mixture after hydro
bvPLA2 with one (M26 or M34) and two oxy-Met residues (M26/M34 and M8
contains unreacted excess of PMAc. Identiﬁcation of all species has been pe
Fig. 3. Comparison between RP-HPLC traces of bvPLA2-PMAc
mixture (molar ratio 1–5) after 10 min (A) and 60 min (B) of
incubation. Fractions 2 and 1 correspond to the bvPLA2 with one
(M26 or M34) and two oxy-Met residues (M26/M34 and M86),
respectively; fraction 3 represents the bvPLA2-PM adduct and fraction
4 corresponds to the unreacted excess of PMAc. It should be noted
that the protein species with two oxy-Met residues is not aﬀected by
PM. M86, the second oxy-Met, lies in the proximity of the active site,
protruding its side chain towards the pocket where PM binding takes
place; we consider therefore likely that the extra oxygen atom may
interfere with optimal positioning of PM for covalent binding (see also
[9])
272 M.C. Monti et al. / FEBS Letters 578 (2004) 269–274before LC-MS analysis. In this case, a reduced species, stable
under acidiﬁcation (as expected for an amine vs. an imine)
and featuring a mass increment of 444 Da with respect to
the free bvPLA2, was detected.
An additional evidence for the bvPLA2-catalyzed conversion
of PMAc to PM, and its subsequent covalent reaction with the
enzyme, came from isolation of PM-oxyme by LC-MS upon
treatment of the PMAc-bvPLA2 incubation mixture with ex-
cess hydroxylamine (NH2OH) for 2 h at 37 C. Fig. 4 displays
the LC-MS run relative to the latter experiment, showing the
disappearance of the covalent bvPLA2-PM complex and the
formation of the peak relative to PM-oxyme. It should be
noted that PMAc itself is not reactive towards hydroxylamine,
as expected for an ester. On the other hand, PM, both in its
free and bvPLA2-bound forms, should be trapped by the reac-
tion with hydroxylamine, as previously found for other alde-













Taken together, these evidences allowed us to conﬁrm the
plausible hypothesis that bvPLA2, after an initial non-covalent
interaction with PMAc, may work as a generic lipid esterase
reactivating the C-25 aldehyde functionality. This PLA2-cata-xylamine (NH2OH) treatment. Fractions 2 and 1 correspond to the
6), respectively; fraction 3 corresponds to PM-oxyme (3) and fraction 4
rformed by ESI-MS data.
Da
Da
Scheme 2. Plausible mechanisms of bvPLA2 inactivation by D3-PMAc involving PLA2-mediated hydrolysis of 25-acetate and 24-acetate,
respectively, along with the expected mass increments.
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tive PM with the consequent covalent inhibition of the enzyme,
as already shown in our previous work [9]. This suicide mech-
anism postulated on the basis of these considerations (Scheme
1) gives evidence of the formation of an imine intermediate, as
conﬁrmed by the mass increment of 444 Da observed for the
modiﬁed PLA2 species (after reduction) [9,10].
A control experiment, designed to probe PMAc selectivity
towards bvPLA2, was performed by adding to the usual incu-
bation mixture (bvPLA2 + PMAc) an excess of a second pro-
tein featuring a number of exposed lysine residues in its
sequence. The purpose of the experiment was to monitor
whether in these forcing conditions, PMAc (and hence PM)
was still able to display a clear binding preference towards
PLA2, by virtue of a speciﬁc PM-PLA2 recognition process.
Alternatively, PM may be trapped by an aspeciﬁc reaction of
its aldehyde function with an exposed Lys-e-NH2 group. The
results (data not shown) showed that no PM-lysozyme adduct
could be detected by HPLC-DAD up to 5:1 lysozyme-bvPLA2
molar excess, conﬁrming the strong and speciﬁc aﬃnity of PM
towards bvPLA2.
The only issue that remained to be sorted out was whether or
not the PLA2 mediated de-acetylation process was carried out
speciﬁcally at C-25. As a matter of fact, at least in principle,
the hydrolytic process may also involve the 24-acetate, since
also in this case another cyclic hemiacetal functionality (again
an aldehyde in disguise) would be generated, therefore exposing
another potential site for nucleophilic attack of an amino
group. It has to be pointed out, however, that all the evidences
gathered so far on the chemistry and biology of the whole fam-
ily of petrosaspongiolides revealed that C-25 is much more
prone to undergo attacks from nitrogen nucleophiles [8,10],
possibly as a consequence of reduced steric hindrance at this
location. On the other hand, it should be noted that an MS ap-
proach does not allow to distinguish between hydrolytic cleav-
ages at C-24 and C-25. For a conclusive, direct proof that this
was indeed the case also for PMAc, a suitable labeling of the 25-acetate group, for instance a deuterated sample, was therefore
necessary for an MS discrimination among the two possible
reaction pathways (Scheme 2). To this end, 25-[D3]acetyl-PM
(D3-PMAc) was ﬁrst prepared and then incubated with
bvPLA2. Application of our usual LC-MS characterization
protocol yielded, upon PLA2 covalent modiﬁcation, a 442 Da
mass increment, as typically observed for PMAc (or even intact
PM). No sign at all of MS peaks with mass increments of 445
Da, as expected for molecular species undergoing 24-acetate
hydrolysis, was detected. Such observation enabled us to con-
clude that the deuterium-containing 25-acetate was entirely lost
upon exposure of the D3-PMAc to bvPLA2.
In conclusion, the serendipitous discovery of the manifestly
diﬀerent chemical behavior of the 25-acetate, with respect to
the chemically similar 24-acetate of the same molecule, ap-
peared to us as a relevant ﬁnding. First, the found PLA2 selec-
tivity in acting as a generic esterase raises intriguing
speculations on its origin. If PLA2 ability to catalyze the
hydrolysis of an acetate is certainly not a remarkable ﬁnding,
the observed discrimination among two chemical functional-
ities of the same kind and located in the same region of the
molecule may be the consequence of speciﬁc three-dimensional
positioning of the inhibitor within the binding pocket.
Moreover, this work may pave the way to the design of a
family of new PLA2 suicide inhibitors, which may be useful
leads for the development of pro-drugs to treat inﬂamma-
tion-related diseases. A complication of this design, however,
may be the potential metabolic instability of PMAc in vivo.
If this compound happens to be also a substrate of other ester-
ases contained in plasmatic ﬂuids, this could prevent intact
PMAc to reach the site of inﬂammation. On the other hand,
the modulation of speciﬁc biological and pharmacological
properties of PM, such as bioavailability, half-life in vivo, tis-
sue selectivity, etc., may be achieved by a wise selection of the
chemical nature of the C-25 ester. The preparation of library of
diﬀerent C-25 esters may be very instrumental to this particu-
lar goal and is underway in our laboratory.
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